Media stories about Tandem Diabetes Care (NASDAQ:TNDM) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tandem Diabetes Care earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the medical device company an impact score of 46.5750575713517 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
A number of analysts have issued reports on the company. Robert W. Baird reiterated a “hold” rating and issued a $3.00 price target on shares of Tandem Diabetes Care in a research report on Sunday, November 19th. Zacks Investment Research cut Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Wedbush reaffirmed an “outperform” rating and set a $17.00 price target (down previously from $50.00) on shares of Tandem Diabetes Care in a research note on Tuesday, October 10th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $15.00 price target on shares of Tandem Diabetes Care in a research note on Friday, October 6th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $11.29.
Tandem Diabetes Care (TNDM) traded down $0.08 during midday trading on Monday, hitting $2.59. The stock had a trading volume of 168,200 shares, compared to its average volume of 201,141. Tandem Diabetes Care has a 12 month low of $2.15 and a 12 month high of $30.00. The company has a debt-to-equity ratio of -2.70, a current ratio of 1.90 and a quick ratio of 0.88.
Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, October 26th. The medical device company reported ($3.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.74) by $0.65. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 79.45%. The company had revenue of $27.00 million for the quarter, compared to the consensus estimate of $25.92 million. During the same quarter in the previous year, the business earned ($0.97) EPS. Tandem Diabetes Care’s revenue was up 119.7% compared to the same quarter last year. equities research analysts forecast that Tandem Diabetes Care will post -15.37 earnings per share for the current year.
In other news, CEO Kim D. Blickenstaff bought 285,700 shares of Tandem Diabetes Care stock in a transaction on Friday, October 13th. The shares were purchased at an average price of $3.50 per share, for a total transaction of $999,950.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 20.90% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/04/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-tandem-diabetes-care-tndm-stock-price.html.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc and related companies with MarketBeat.com's FREE daily email newsletter.